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Removal of uracil by uracil DNA glycosylase limits
pemetrexed cytotoxicity: overriding the limit with
methoxyamine to inhibit base excision repair
AD Bulgar1, LD Weeks1, Y Miao1, S Yang2, Y Xu2,3, C Guo1, S Markowitz1,2,3,4, N Oleinick2,5, SL Gerson1,2 and L Liu*,1,2

Uracil DNA glycosylase (UDG) specifically removes uracil bases from DNA, and its repair activity determines the sensitivity of the
cell to anticancer agents that are capable of introducing uracil into DNA. In the present study, the participation of UDG in the
response to pemetrexed-induced incorporation of uracil into DNA was studied using isogenic human tumor cell lines with or
without UDG (UDG þ / þ /UDG/). UDG/ cells were very sensitive to pemetrexed. Cell killing by pemetrexed was associated
with genomic uracil accumulation, stalled DNA replication, and catastrophic DNA strand breaks. By contrast, UDG þ / þ cells
were 410 times more resistant to pemetrexed due to the rapid removal of uracil from DNA by UDG and subsequent repair of the
resultant AP sites (abasic sites) via the base excision repair (BER). The resistance to pemetrexed in UDG þ / þ cells could be
reversed by the addition of methoxyamine (MX), which binds to AP sites and interrupts BER pathway. Furthermore, MX-bound AP
sites induced cell death was related to their cytotoxic effect of dual inactivation of UDG and topoisomerase IIa, two genes that are
highly expressed in lung cancer cells in comparison with normal cells. Thus, targeting BER-based therapy exhibits more
selective cytotoxicity on cancer cells through a synthetic lethal mechanism.
Cell Death and Disease (2012) 3, e252; doi:10.1038/cddis.2011.135; published online 12 January 2012
Subject Category: Cancer

Pemetrexed, an antifolate, inhibits several key folate-dependent enzymes in the thymidine and purine biosynthetic
pathways, leading to the accumulation of dUMP and the
misincorporation of uracil into DNA.1–3 Incorporated uracil
bases are recognized and excised by uracil DNA glycosylase
(UDG).4–6
UDG is a conserved DNA repair protein expressed in all
types of human cells.7 It specifically removes uracil from DNA
and protect cells from cytotoxicity and mutagenicity. Human
UDG is encoded by the UNG gene. Alternative promoter
usage and splicing of this gene produces two different
isoforms: the mitochondrial UNG1 and the nuclear UNG2.8
Nuclear UDG (UNG2) is the predominant form in cells and
represents 490% of the total enzyme activity. Therefore,
UDG used in this article refers to UNG2. Nuclear UDG activity
is subject to cell cycle–dependent regulation and shows a
marked increase during the S-phase.9 During the S-phase,
UDG is localized in replication foci and interacts with PCNA
(proliferating cell nuclear antigen) and RPA (replication
protein A), two proteins that are required to form functional
replication forks.9 This suggests that the UDG removal of
incorporated uracil may directly link to the progression of the
replication fork.10,11 In addition, UDG has recently been
shown to promote the assembly of human centromere protein
A (CENP-A). As CENP-A is an essential protein required for

chromosome segregation during mitosis, the association
between UDG and CENP-A implies that UDG may be involved
in cell proliferation.12
The base excision repair (BER) pathway is initiated
following the removal of a base lesion by a DNA glycosylase.13 Glycosylase excision of the damaged base proceeds
via hydrolytic cleavage of the N-glycosidic bond, leaving the
sugar–phosphate backbone intact and producing an abasic
site (AP site).14,15 The resultant AP site is processed by AP
endonuclease 1 (APE1), which generates a single-strand
break containing a 50 -dRP residue and a 30 -hydroxyl group.
The completion of BER occurs by short-patch (single
nucleotide) or long-patch (2–13 nucleotides) repair pathways
involving DNA polymerase gap filling and DNA ligation. BER is
the most efficient mechanism for repairing a variety of base
lesions, including those induced by chemotherapeutic agents,
thereby rendering tumor cells resistant to DNA-damaging
chemotherapeutic agents.16–18 To overcome BER-conferred
drug resistance, methoxyamine (MX) has been developed as
an active inhibitor of BER.19 MX reacts specifically with the
aldehyde group in the sugar moiety of the AP site, forming an
MX-bound AP-site. This structurally modified AP site is
refractory to the repair activity of APE1,20,21 leading to the
interruption of the BER pathway. MX has been shown to
potentially enhance the therapeutic efficacy of various
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in UDG þ / þ and UDG/ cells. We first confirmed the UDG
activity in these cells using an in vitro glycosylase cleavage
assay, in which oligonucleotide substrates containing uridine
residues were incubated with either purified UDG/APE1
enzymes or cell extracts. As shown in Figure 1a, after the
reaction with fluorescent probe-labelled oligonucleotide
substrates (40-mer) containing U:G mispairs, both purified
UDG/APE1 enzymes and cell extracts from UDG þ / þ cells
produced cleaved DNA fragments as an 18-mer band, which
resulted from the removal of uracil bases by UDG and
subsequent incision of the resultant AP sites by APE1. By
contrast, no cleaved fragments were observed in UDG/
cell extracts after incubation with an even higher
concentration of cell extracts. Dflag cells were capable of
removing uracil bases, which were derived from UDG/
cells by restoring UDG activity.
We next determined the levels of uracil in the DNA of
UDG þ / þ and UDG/ cells following pemetrexed exposure
using HPLC/MS/MS. There was an inverse relationship
between UDG activity and the level of uracil bases in the
DNA (Figure 1b). A significant amount of uracil was detected
in UDG/ cells, which correlated with the duration of

DNA-damaging chemotherapeutic agents.22–25 It is currently
being evaluated in multiple clinical trials (as TRC102,
TRACON Pharmaceuticals, Inc., San Diego, CA, USA)
and has completed phase-I testing in combination with
pemetrexed.
In the present study, we investigated the impact of UDG and
BER on cell sensitivity to pemetrexed using isogenic UDGproficient and -deficient human cancer cells. Although pemetrexed has multiple targets, the different responses to pemetrexedin UDG þ / þ and UDG/ cells were investigated only with
respect to the levels of uracil-DNA produced by pemetrexed.
We also explored the inhibition of BER by MX as a novel
strategy to enhance the therapeutic efficacy of pemetrexed,
although MX is expected to potentiate other anticancer agents
capable of inducing uracil incorporation into DNA.

Results
UDG activity determines the level of uracil retained in
DNA. To correlate UDG activity with the cytotoxicity
of pemetrexed, comparative studies were performed
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Figure 1 UDG activity determines the levels of uracil and AP sites in DNA. (a) UDG activity assay in vitro. Oligonucleotide duplexes containing U:G were incubated with
cell extracts (5–10 mg) from UDG þ / þ , DLD1flag, and UDG / cells at 371C for 1 h. Reaction products were resolved by electrophoresis through denaturing 20%
polyacrylamide gels. (b) Incorporated uracil detected in UDG þ / þ and UDG/ cells by HPLC/MS/MS analysis. Cells were treated with pemetrexed (10 mM) for 6, 24, 48, and
72 h. Cells were harvested and 40 mg of extracted DNA were in vitro reacted with purified UDG (10 U) for 2 h. (c) Cells were treated with 5-FU (10 mM) for 6, 24, 48, and 72 h.
Uracil was quantified in the reaction product by LC-MS analysis. (d) AP site formed by pemetrexed in UDG þ / þ and UDG/ cells. Cells were treated with pemetrexed
(0–400 nM) for 24 h. DNA was extracted and AP sites measured by ARP reagent. (e) AP site detected in DNA of UDG/ cells after reacted with purified UDG in vitro. Cells
were treated with pemetrexed (0–100 nM) for 24 h and 40 mg DNA extracted from cells was in vitro reacted with purified UDG (10 U) for 2 h and AP sites were measured
using ARP. Results are representative of three independent experiments
Cell Death and Disease
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pemetrexed exposure. By contrast, the detectable uracil in the
DNA was very low in UDG þ / þ cells, suggesting rapid and
efficient removal of the incorporated uracil. Similarly, a greater
retention of uracil in UDG/ cells than in UDG þ / þ cells
(Figure 1c) was detected following exposure to 5-fluorouracil
(5-FU), a well-known thymidylate synthase inhibitor capable
of introducing uracil into DNA through imbalanced nucleotide
pools.
The AP sites formed by pemetrexed were measured in
cells, which are a surrogate marker for UDG activity in the
cells. As shown in Figure 1d, a dose-dependent formation of
AP sites in DNA was detected in UDG þ / þ but not in UDG/
cells. The lack of detectable AP sites in UDG/ cells is
presumably due to the absence of UDG activity to remove
uracil, resulting in the accumulation of uracil bases in the DNA.
To confirm this, pemetrexed-induced AP sites in UDG/ DNA
were analyzed after incubation with purified UDG enzymes in
vitro. As shown in Figure 1e, increased AP sites were detected
as a function of pemetrexed doses.
UDG
activity
determines
cell
sensitivity
to
pemetrexed. To determine the correlation between the
expression of UDG and the sensitivity to pemetrexed, the
cytotoxic effect of pemetrexed was examined in UDG þ / þ and
UDG/ cells with a clonogenic assay. UDG/ cells were 10
times more sensitive to pemetrexed than UDG þ / þ cells
(Figure 2a). The IC50 value for pemetrexed was 20 nM in
UDG/ cells, compared with 210 nM in UDG þ / þ cells. The
killing effect of pemetrexed in UDG/ cells was reversed
when UDG activity was restored in Dflag cells. Similarly,
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Figure 2 Comparison of cell sensitivity with chemotherapeutic agents between
UDG þ / þ and UDG/ cells. The cytotoxicity induced by different chemotherapeutic agents was analyzed by clonogenic formation assay in UDG-proficient
or -deficient cells (a) pemetrexed treatment (0–400 nM); (b) 5-FU treatment
(0–20 mM); (c) temozolomide treatment (0–1500 mM; P-value ¼ 0.687); and
(d) cisplatin treatment (0–40 mM, P-value ¼ 0.753). Results are representative of
three independent experiments

UDG/ cells were more sensitive to 5-FU than either
UDG þ / þ or Dflag cells (Figure 2b). By contrast, there was
no significant difference in sensitivity to temozolomide, an
alkylating agent, or cisplatin, a crosslinking agent (Figures 2c
and d), between UDG þ / þ and UDG/ cells. Thus, results
suggest that UDG activity specifically impacts the cytotoxicity
of anticancer agents that are capable of inducing the
incorporation of uracil bases in DNA.
The accumulation of incorporated uracil in DNA stalls
DNA replication. To elucidate the underlying mechanisms
responsible for pemetrexed’s cytotoxicity, we first examined
cell cycle progression in response to pemetrexed. As shown
in Figure 3a, pemetrexed (25 nM) caused the arrest of B25%
and 36% of UDG/ cells in the S-phase at 6 and 24 h,
respectively (Figure 3a). The S-phase arrest lasted more
than 72 h. At this time point, 35% of the cells were still in the
S-phase and B22% of the cells had undergone apoptosis
(subG1). By contrast, progression of the cell cycle in
UDG þ / þ cells was only slightly affected by this dose of
pemetrexed (Figure 3b). The effect of pemetrexed on cell
killing was further analyzed by annexin V staining at 24 h
after cells were treated with 50 nM of pemetrexed. Results
revealed that pemetrexed at the same concentration induced
30% of cell death in UDG/ cells compared with 5% in
UDG þ / þ cells (Figures 4a and b).
We next examined a network of proteins responsible for
DNA damage checkpoints following exposure to pemetrexed.
We found that phospho-Chk1 (Ser345) was significantly
increased in UDG/ cells (Figure 3c) but not in UDG þ / þ
cells (Figure 3d). As a DNA damage checkpoint kinase, the
induction of phosphor-Chk1 suggests that pemetrexed stalls
replication forks in UDG/ cells. We also noted that in both
cell lines, phospho-histone H3 (Ser 10), a mitotic marker,
increased at 6 h and decreased at 24 h following exposure to
pemetrexed. Interestingly, the periodic fluctuation of phosphorylation of histone H3 was not directly associated with
mitotic cell cycle progression. In addition, the induction of
phospho-histone H3 was concomitant with the increase in
G1–S-phase–specific cyclin D1. Subsequently, the S-phase–
specific cyclin E was upregulated following the exposure to
pemetrexed (Figures 3c and d). It has been reported that
inhibition of cell proliferation can regulate histone H3
phosphorylation and that this modification enables the
transcription of genes that are activated as a consequence
of a variety of cell-signaling events.26 Therefore, our data may
suggest that phosphorylation of histone H3 is an important
regulatory mechanism of gene transcription. However,
whether the phosphorylation of histone H3 is linked to
transcriptional activation of cyclin proteins in response to
DNA damage induced by pemetrexed needs to be further
investigated. Although the role of cyclin D1 and E remains to
be fully elucidated, they function as the regulators of the G1–S
phase entry in response to inhibition of replication-stalled
S-phase. Furthermore, the upregulation of phosphor-cdc2
and cyclin B1 also indicates that pemetrexed-induced DNA
damage activates the S- and M-phase checkpoints.
In addition, pemetrexed induced an increase in the
expression of topoisomerase IIa (topo IIa) that was
much greater in UDG/ cells than in UDG þ / þ cells
Cell Death and Disease
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Figure 3 Cellular response to uracil-DNA induced by pemetrexed. Comparison of cell cycle progression before and after treatment with pemetrexed between (a) UDG/
and (b) UDG þ / þ cells. Protein alterations in the response to DNA damage, cell cycle progression, and cell death were detected in (c) UDG/ cells and (d) UDG þ / þ cells
treated with pemetrexed. Cells were collected at 6 and 24 h after pemetrexed treatment. Results are representative of two independent experiments

(Figures 4c and d). The induction of topo IIa may be
associated with either a global signal of DNA damage or a
more specific response to the S-phase arrest. As expected,
gH2AX was markedly increased in UDG/ cells, which is a
well-known marker of DNA double-strand breaks (DSBs) and
an indicator of stalled replication forks and replication fork
collapse.27 In company with the induction of gH2AX, a
significant cleaved PARP (a hallmark of apoptotic cell death)
was detected in UDG/ cells. The activation of caspase 3, 8
and 9 (Figures 4c and d) was then measured. Those are
considered to be the key effect of proteases on apoptosis
through the degradation of numerous cellular substrates
including the cleavage of PARP. Surprisingly, the pemetrexed-induced PARP cleavage appeared to be independent
of the caspase pathway. Moreover, survivin was noted to be
upregulated in response to pemetrexed. As a member of the
inhibitor of apoptosis protein family, survivin has been
reported to bind to and inhibit effector caspase-3 and -7.28
Although the direct effect on caspases still remain to be further
determined, the induction of survivin may link to the inhibition
of caspase 3. Taken together, our results suggest that
pemetrexed-induced apoptotic cell death may not be
mediated through the caspase pathway or that other cell
death regulators are more important in pemetrexed-treated
cells.29
Cell Death and Disease

We further investigated whether uracil-DNA lesions could
inhibit DNA replication. Cells were sequentially labeled with
the halogenated nucleotides chlorodeoxyuridine (CldU) and
iododeoxyuridine (IdU) to stain replication foci. Representative cells are depicted in Figures 5b and c. Compared with
replication foci stained with CldU and IdU in untreated cells, a
significant reduction in IdU incorporation was observed in
UDG/ cells following a 6-h exposure to pemetrexed and a
further 18-h after incubation, suggesting that pemetrexedinduced accumulation of uracil has the potential to inhibit DNA
replication. By contrast, there was no significant change in
CldU and IdU incorporation in the replication foci of UDG þ / þ
cells before and after pemetrexed treatment (25 nM). The
fluorescence density of IdU or CldU was quantified in UDG/
and UDG þ / þ cells by using the NIH Image J software (NIH,
Bethesda, MD, USA; Figure 5d). The values of the ratio of IdU
to CldU indicate that accumulated uracil bases in DNA block
DNA replication in UDG/ cells.
Blocking BER enhances pemetrexed cytotoxicity. We
have shown above that the lack of UDG activity sensitizes
tumor cells to antimetabolites. However, UDG deficiency
appears to be surprisingly rare in human tumors. In fact,
human lung cancer express higher UDG than its
corresponding normal tissues.30–32 Thus, the removal of
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Figure 4 Pemetrexed-induced apoptotic death is independent of caspase pathway. The percentage of cell death induced by pemetrexed using Annexin V staining in
UDG/ (a) and UDG þ / þ cells (b). Protein alterations involved in regulation of apoptotic cell death were detected in (c) UDG/ cells and (d) UDG þ / þ cells treated with
pemetrexed. Cells were collected at 6 and 24 h after pemetrexed treatment. Results are representative of two independent experiments

uracil by UDG and subsequent BER activity limits the efficacy
of pemetrexedin lung cancer treatment. We next studied a
therapeutic strategy to override the UDG-conferred
resistance to pemetrexed by interrupting the BER pathway
using MX. Cytotoxicity was measured in UDG þ / þ and
UDG/ cells after treatment with pemetrexed alone or in
combination with MX. MX greatly sensitized UDG þ / þ cells to
pemetrexed and reduced the pemetrexed IC50 value from
220 to 80 nM (Figure 6a). By contrast, no differential
sensitivity between pemetrexed alone and in combination
with MX was observed in UDG/ cells (Figure 6b). The
failure of MX to potentiate pemetrexed toxicity in UDG/
cells can be explained by the fact that, in UDG/ cells, there
are no DNA-binding sites available for MX due to the
absence of AP sites in the DNA (Figure 1d). Similar
experiments were performed in the human nonsmall cell
lung cancer cell lines H460 and A549 (Figures 6c–e). These
two cell lines retain wild-type p53 and harbor a mutation in
K-ras but express different levels of UDG. Western blotting
revealed that UDG protein levels in A549 were approximately
9- and 17-fold higher than in H460 cells and normal lung
epithelial cells, respectively (Figure 6d). A549 cells were
obviously more resistant to pemetrexed than H460 cells. IC50
values for pemetrexed were 1200 nM in A549, compared with

110 nM in H460 cells. MX was capable of enhancing
pemetrexed cytotoxicity in both cell lines four- to fivefold
(Figure 6e). Thus, although multiple mechanisms may confer
resistance to pemetrexed, our results indicated that UDG
activity in lung cancer cells is an important factor in
pemetrexed-resistance. This was further confirmed by the
studies, in which UDG, in H460 cells, was knocked down by
siRNA, resulting in the increase in cytotoxicity by threefold
(data not shown). Importantly, MX reverses this resistance.
AP sites were detected in H460 cells following treatment
with pemetrexed. As shown in Figure 7a, the formation of AP
sites increased as the concentration of pemetrexed increased. Co-treatment with MX formed MX-bound AP sites,
resulting in the reduction of ARP (aldehyde-reactive probe)detected AP sites. This is because ARP and MX react
competitively with the aldehyde group in AP sites and binding
of MX to the AP sites makes them unavailable for ARP binding
(Figure 7a). Furthermore, the levels of UDG protein were
significantly induced in cells treated with the combination of
pemetrexed and MX (Figure 7b). Immunofluorescent staining
revealed that the UDG protein was increased in both the
cytosol and the nucleus but predominantly accumulated in the
nucleus at 24 h after treatment with the combination
(Figure 7c), suggesting that MX-bound AP sites were able to
Cell Death and Disease
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Figure 5 Inhibition of DNA replication induced by pemetrexed. (a) Schematic diagram of the CldU, pemetrexed and IdU pulse treatments. (b) UDG/ and (c) UDG þ / þ
cells were fixed at 6 and 24 h after treatments and subjected to fluorescent immunostaining. Replication foci were labeled with CldU (green) and IdU (red). Results are
representative of two independent experiments. (d) The ratio of IdU to CldU was measured as the ratio of the mean fluorescent density of IdU versus CIdU for each cell
(n ¼ 40)

trap or stabilize UDG in DNA. In addition, concomitant
inductions of topo IIa, gH2AX, and cleaved PARP were seen
in cells treated with the combination of pemetrexed and MX
(Figures 7d and e). These results could be explained by our
previous findings that MX-bound AP sites were capable of
poisoning topo IIa and inducing topo IIa-mediated DNA
DSBs,33 triggering apoptosis.

MX potentiates the anti-tumour effects of pemetrexed
in vivo. The MX-potentiated antitumour effect of
pemetrexed was further tested in vivo using human lung
cancer xenografts. As shown in Figure 8, both H460 and
A549 tumors were moderately sensitive to pemetrexed
alone. However, the antitumour activity of pemetrexed was
significantly enhanced by the combination of pemetrexed
(150 mg/kg) and MX (4 mg/kg) in these two xenograft tumors.
At 15 days, H460 xenografts treated with PBS (control group)
had a mean tumor volume of 2100±106 mm3, compared
with a mean tumor volume of 1726±176 mm3 or
Cell Death and Disease

543±82 mm3 (*P-valueo0.02) in mice treated with either
pemetrexed alone or in combination with MX, respectively.
Similarly, MX-potentiated antitumor effect of pemetrexed
was observed in A549 xenografts, which was consistent with
the in vitro data. In addition, at these doses, mice did not
present evidence of systemic toxicity as evaluated by body
weight measurements and complete blood count tests (data
not shown).
Discussion
The current study provides evidence that UDG has a profound
impact on the cytotoxicity of uracil incorporation into DNA
induced by pemetrexed. Because the expression of UDG in
lung cancer tissue is high but varies between individuals, UDG
activity may be exploitable as a biomarker for predicting
susceptibility and response to pemetrexed-related treatment. Moreover, our results demonstrated that the loss of
UDG results in the accumulation of uracil in DNA, which
stalls replication forks and subsequently induces replication
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collapse, leading to remarkable increases in the killing effect
of pemetrexed. These studies lead us to propose that, as a
therapeutic target, UDG may offer new avenues for the
development of novel anticancer agents.

UDG removal of incorporated uracil links the DNA
replication process. The progression of the DNA
replication fork can be stopped by various factors, including
DNA damage, protein–DNA complexes, and depletion of
Cell Death and Disease
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nucleotide pools. It has been reported that the role of BER
becomes critical when damaged bases are produced or
persist at replication forks.34 On the basis of our results, we
suggest that the accumulation of uracil bases in DNA would
stall DNA replication forks, which immediately activates DNA
damage checkpoint pathways and robust mechanisms of
DNA damage repair. The following lines of evidence support
this conclusion. First, using UDG þ / þ and UDG/ cells, we
demonstrated that crosstalk between uracil incorporation and
DNA damage checkpoints was mediated by UDG. When
uracil bases were present in DNA, particularly at replication
forks, the DNA damage checkpoint appeared to use the ATR/
chk1–cyclin/cdk network to stop damaged cells in the S- or
M-phase until repairs were made (such as through efficient
repair by UDG) or to trigger cell death if repairs could not be
made (as in UDG-deficient cells). Second, a fundamental
level of coordination between BER and DNA replication is
supported by evidence that BER proteins are active during
DNA replication. In particular, nuclear UDG has been
recently discovered to localize in replication foci to form a
Cell Death and Disease

multiprotein complex with RPA and PCNA, both of which are
involved in various aspects of DNA replication.9,10
UDG-initiated BER operates at replication foci, suggesting
that UDG-mediated repair may directly and indirectly affect
the progression of DNA replication.35 Third, a significant
increase in the expression of topo IIa was observed in
response to pemetrexed exposure. Topoisomerases sustain
the progression of the replication machinery by removing
supercoils ahead of the replication fork. The induction of topo
IIa may indicate that the progression of DNA replication is
halted by pemetrexed-induced DNA damage. In UDG/
cells, gH2AX and PARP cleavage were concomitantly
increased with induction of topo IIa, suggesting that
replication fork collapse occurs when the replication
machinery arrives at the uracil-containing DNA template,
leading to cell death. By contrast, UDG þ / þ cells were more
resistant to topemetrexed-induced cell death.
UDG activity determines the levels of AP sites, key
targets of MX. When uracil bases are present in DNA, UDG
makes almost all of its contacts with the uracil-containing
DNA strand. The binding of UDG transiently forces DNA to
undergo local distortions to flip out the uracil base.35 By
contrast, normal bases resist the distortion, so that the UDG
active site only allows uracil to bind in extra helical DNA,
facilitating the UDG enzymatic excision to produce AP sites.
Interestingly, UDG remains bound to the AP site after
releasing the uracil base until the AP site is transferred to
APE1, thereby displacing UDG from an AP site. In fact,
binding of UDG to its AP site result in the inactivation of UDG
activity because the dissociation of UDG from the AP site by
APE1 is a rate-limiting step. When MX is present, MX rapidly
binds to AP sites and makes them unrecognizable by APE1,
blocking the crosstalk of APE1 with other BER proteins and
interrupting BER activity. Importantly, the failure of
recognition of MX-bound AP sites by APE1 would result in
trapping/stabilising UDG in DNA. Although speculative, it is
possible that the exceptionally strong binding of UDG to MXbound AP sites forms protein–DNA complexes, leading to the
obstruction of replication and catastrophic DNA DSBs. This is
consistent with our observation that the combination of
pemetrexed and MX induced UDG that was predominantly
located in the nucleus, accompanied by a significant increase
in gH2AX. In addition to stopping the progression of DNA
replication, MX-AP sites are also capable of poisoning topo
IIa and inducing topo IIa-mediated DNA DSBs.36–39 Because
production of the lethal MX-AP site depends on UDG activity,
UDG is an essential factor for MX-potentiation of pemetrexed
cytotoxicity.
Targeting
UDG/BER
enhances
cytotoxicity
of
pemetrexed through a synthetic lethal mechanism. A
synthetic lethal mechanism, in which tumor cells, but not
normal cells, are specifically targeted for killing is highly
attractive. The concept of synthetic lethality is based on the
reliance of cancer cells on DNA repair to maintain cell
division. Because cancer cells are ‘addicted’ to DNA repair,40
inhibiting DNA repair impedes cancer cell replication, leading
to cell death. The present study demonstrates that targeting
BER with MX enhances pemetrexed cytotoxicity by the dual
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inactivation of UDG and topo IIa, through trapping in MX-AP
sites. As the expression of UDG and topo IIá is much higher
in tumor cells than in normal bone marrow cells,33,36 the
MX-potentiated synergistic killing effect can be exploited to
minimize hematopoietic toxicity. Therefore, BER-targeted,
synthetic lethal anticancer therapy has important clinical
implications.
Materials and Methods
Cells and reagents. Stable and complete knockdown of UDG expression in
DLD1 colon cancer cells (DLD1/UDG/ cells) was achieved by homologous
recombination, as described by Zhang et al.41 Briefly, homologous recombination
resulted in insertion of a DNA construct containing a series of stop codons within
Exon 1 of the UNG gene to interrupt transcription of both the mitochondrial and
nuclear UNG isoforms. Recombinant virus was grown in 293T cells and
subsequently used to infect DLD1 cells. Selection of positively transfected clones
was achieved by the addition of G418 to the culture medium. A second infection of
transfected clones with Cre-recombinase adenovirus caused excision of the
neomycin-resistant cassette. Dflag cell line was produced by transfection of UDG
expression vector in UDG/ cells to restore UDG activity.
Pemetrexed was obtained from LC Laboratories (Woburn, MA, USA),
5-Fluorouracil and cisplatin were purchased from Sigma-Aldrich (St. Louis, MO,
USA) and temozolomide was purchased from Ochem Inc. (Des Plaines, IL, USA).
Uracil DNA glycosylase was purchased from New England Biolabs (Ipswich, MA,
USA) and APE1 was purchased from Trevigen (Gaitherburg, MD, USA). MX, uracil,
and uracil-1,3-15N2 were purchased from Sigma-Aldrich. MX was dissolved in
sterilized water (pH 7.0) at a stock solution of 2.5 M and stored at 201C. Working
solutions were generated before experimental use. Fluorescent dye-labeled 40-mer
oligonucleotides containing U:G mispairs were purchased from Operon Biotechnologies (Huntsville, AL, USA).
Colony survival assay. Tumor cells (500–2000/dish) were plated and treated
with pemetrexed (0–400 nM), 5-FU (0–20 mM), temozolomide (0–1500 mM), or
cisplatin (0–40 mM). After 7 days, surviving colonies were stained with methylene
blue for 30 min at room temperature and the colonies containing more than 50 cells
were counted to generate survival curves.
Glycosylase activity assay. UDG activity (purified protein or whole-cell
extracts) was measured using an oligodeoxynucleotide containing a single uracil.
50 -[HEX]GTAAAACGACGGCCAGTGUATTCGAGCTCGGTACCCGGGG
30 -CATTTTGCTGCCGGTCACGGAAGCTCGAGCCATGGGCCCC[Cy5].
The fluorescent dye-labeled duplex oligonucleotides were incubated with purified
UDG at 371C for 30 min, followed by 30 min incubation with APE1 or with whole-cell
extract. The reaction was stopped by incubation at 951C for 5 min. Reaction products,
18-mer fragments, were resolved by electrophoresis on denaturing 20%
polyacrylamide gels (7 M urea, 1  Tris-borate-EDTA). Visualization and quantitation
was achieved using a Typhoon 9200 fluorescence Imager (Amersham BioScience,
Piscataway, NJ, USA). UDG activity was determined based on fluorescence density
quantified using the ImageQuant software (Amersham BioScience).
AP site assay. The number of AP sites was measured using ARP reagent. The
assay was performed as previously described.42 Briefly, cells (2  106) were
collected after drug treatment and DNA was extracted. DNA (10 mg) was incubated
with 15 ml of 1 mM ARP (Dojindo Laboratories, Kumamoto, Japan), and then
precipitated and washed with ice-cold ethanol. The ARP-labeled DNA was then
heat-denatured at 1001C for 5 min, quickly chilled on ice and mixed with an equal
volume of 2 M ammonium acetate. The DNA was then immobilized on a BA-S 85
nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany) using a
minifold II vacuum filter device (Schleicher and Schuell). The membrane was
incubated with 0.25% BSA-PBS containing streptavidin-conjugated horseradish
peroxidase (BioGenex, San Ramon, CA, USA) at room temperature for 40 min with
gentle shaking. ARP-labeled AP sites were visualized by chemiluminescence
(Amersham) followed by quantitative densitometry using the NIH ImageJ software.
Detection and quantification of uracil using HPLC/MS/MS
analysis. UDG/ and UDG þ / þ cells were exposed to pemetrexed (10 mM)
or 5-FU (10 mM) for 6, 24, 48 and 72 h. At indicated time points, cells were harvested

and genomic DNA was extracted by phenol/chloroform. DNA (40 mg) was incubated
with 10 U of purified UDG (New England Biolabs) in 60 ml of reaction buffer at 371C
for 2 h. The reaction products were dried at 351C in a Turbovap under a stream of
nitrogen and reconstituted in 150 ml 90% acetonitrile. The analyte was retained by an
Atlantis Hilic Silica analytical column (Waters Corporation, Milford, MA USA)
(2.1  100 mm, 3.5 mM) and eluted isocratically by a mixture of 90% acetonitrile and
10% 2.0 mM ammonium formate at a flow rate of 0.2 ml/min. The detection was carried
out by an API 3200 MS/MS mass spectrometer (AB SCIEX, Foster City, CA, USA).
Immunofluorescence microscopy. Cells were grown on coverslips and
were treated with drugs for 6–24 h. Then cells were fixed in 2% paraformaldehyde
and permeabilized with 0.2% Triton X-100. Cells were incubated with primary UDG
(Abcam, Cambridge, MA, USA) or gH2AX (Bethyl, Montgomery, TX, USA) antibody
for 1 h at room temperature, followed by incubation with a secondary antibody
conjugated with Alexa 488 (green) (Molecular Probes, Carlsbad, CA, USA).
The nucleus was stained using Hoechst 33258 for 15 min at room temperature.
Images were digitally captured using an Olympus microscope (Olympus, Westmont,
IL, USA) equipped with a digital camera.
Western blot analysis. Cellular protein was quantified spectrophotometrically
using the Bio-Rad assay. Equal amounts of proteins (30 mg) were separated by
SDS-PAGE and transferred to polyvinylidene fluoride membrane (Millipore Corp.,
Bedford, MA, USA). The membrane was incubated with primary antibody in 1%
nonfat dry milk solution overnight at 41C and followed by the incubation with HRPconjugated secondary antibody at room temperature for 1 h. Proteins were
visualized by ECL (Amersham Corp, Piscataway, NJ, USA) according to the
manufacturer’s instructions. Sources of primary antibody were as follows: cleaved
PARP (BD Pharmingen, San Jose, CA, USA), gH2AX (Bethyl), pChk1, Chk1,
pcdc2, cyclin B1, topo IIa, topoisomerase I, Bax, and Bcl2 (Cell Signaling, Danvers,
MA, USA), phospho-histone H3 (Upstate Biotechnologies, Billerica, MA, USA) and
a-tubulin (Sigma-Aldrich).
Cell cycle analysis. For cell cycle analysis, 106 cells (DLD1/UDG þ / þ and
DLD1/UDG/) were plated in 100-mm tissue culture dishes and exposed to
pemetrexed (25 nM). After 6, 24, and 72 h of culture, cells were fixed with 80%
methanol and washed with ice-cold 1% BSA/PBS. DNA was stained with 20 mg/ml
propidium iodide (Sigma-Aldrich) and 2.5 mg/ml of DNase-free RNaseA (Roche,
Branford, CT, USA). The DNA fluorescence of propidium iodide–stained cells was
measured with an Elite ESP flow cytometer/cell sorter (Coulter, Miami, FL, USA).
Immunofluorescence microscopy of replication foci stained with
CldU and IdU. DNA replication sites were visualized by incorporation of
CldU and IdU into DNA. UDG/and UDG þ / þ cells were labeled with 100 mM
CldU (ICN, Irvine, CA, USA) or IdU (Sigma-Aldrich) for 45 min at different time
intervals. Cells were washed with PBS, fixed with cold 70% ethanol and stored at
41C. For antibody staining, the ethanol was removed, and 100% methanol was
added for 5 min. Cells were washed twice with PBS and incubated with 1.5 M HCl for
30 min to denature the DNA. Cells were washed with PBS, permeabilized with 0.5%
Tween-20 in PBS for 5 min, and then incubated in 5% BSA (Sigma-Aldrich) and in
PBS for 20 min to reduce nonspecific binding. Primary antibodies CldU (rat antiBrdU; Accurate Chemical and Science Co., Westbury, NY, USA) and IdU (mouse
anti-BrdU; BD Biosciences) were diluted in 1% BSA buffer, added to the slides, and
incubated in a humid environment for 2 h. Slides were washed with PBS-Tween20
and then in a high-salt buffer (200 mM NaCl, 0.2% Tween-20, and 0.2% NP-40 in
PBS) for 15 min. The samples were incubated with secondary antibodies for 1 h.
Finally, slides were washed with PBS-Tween 20, mounted with Vectashield antifade
mounting medium (Vector Laboratories, Inc., Burlingame, CA, USA), and stored at
41C. Images were visualized on a Nikon EclipseTE-300 confocal microscope
(Jenoptik Laser Technologies Corp., Brighton, MI, USA). Fluorescence density of
CldU or IdU was quantified by the NIH Image J software.
Xenograft tumors in nude mice. H460 or A549 tumor cells (5  106) were
injected into bilateral flanks of female athymic NCr (nu/nu) mice (6 weeks old). When
the tumor volumes reached 100–150 mm3, mice were divided into control and
treatment groups (6–9 mice/group). Nude mice carrying tumors were treated with
pemetrexed (150 mg/kg) alone, MX (4 mg/kg) alone, or the combination of the two
agents, by daily intraperitonial injection (i.p.) for 5 consecutive days. Tumor
measurements were taken every 2 days. Tumor responses were quantified by
tumor volume.
Cell Death and Disease
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Statistical analysis. Results are presented as the mean±s.e.m. with
significance calculated by Student’s t-test with standard software (GraphPad Prism,
San Diego, CA, USA). Significance was assigned for a P-value o0.05.
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